Genscript Biotech Corporation (HKG:1548)
Hong Kong · Delayed Price · Currency is HKD 36.36
+2.48 (7.32%)
Sep 1, 2026, 4:08 PM HKT
Genscript Biotech Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 79,514 | 27,155 | 21,097 | 42,166 | 52,563 | 72,496 | |
Market Cap Growth | 111.96% | 28.72% | -49.97% | -19.78% | -27.50% | 229.03% |
Enterprise Value | 75,897 | 24,137 | 18,906 | 38,022 | 47,670 | 64,744 |
Last Close Price | 36.36 | 12.42 | 9.84 | 19.86 | 24.85 | 34.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 0.92 | - | - | - |
Forward PE | 132.91 | 41.99 | 257.62 | 257.62 | 257.62 | 257.62 |
PS Ratio | 12.00 | 3.64 | 4.57 | 9.63 | 10.77 | 18.97 |
PB Ratio | 2.60 | 0.88 | 0.63 | 2.64 | 4.95 | 6.70 |
P/TBV Ratio | 2.62 | 0.88 | 0.63 | 3.94 | 6.85 | 9.25 |
P/FCF Ratio | 1555.36 | 14.33 | - | - | - | - |
P/OCF Ratio | 72.65 | 10.72 | 35.90 | - | - | - |
PEG Ratio | - | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 11.45 | 3.23 | 4.09 | 8.68 | 9.77 | 16.94 |
EV/EBITDA Ratio | - | 9.76 | 34.75 | 58.29 | - | - |
EV/EBIT Ratio | - | 12.15 | 262.23 | 185.81 | - | - |
EV/FCF Ratio | 1484.61 | 12.74 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.09 | 0.06 | 0.41 | 0.48 | 0.30 |
Debt / EBITDA Ratio | 1.68 | 1.05 | 2.94 | 8.59 | - | - |
Debt / FCF Ratio | 52.70 | 1.42 | - | - | - | - |
Net Debt / Equity Ratio | -0.12 | -0.12 | -0.09 | -0.53 | -0.59 | -0.71 |
Net Debt / EBITDA Ratio | -2.42 | -1.47 | -5.30 | -13.00 | 2.08 | 2.89 |
Net Debt / FCF Ratio | -71.60 | -1.92 | 3.09 | 2.01 | 2.40 | 3.66 |
Asset Turnover | 0.17 | 0.19 | 0.14 | 0.19 | 0.26 | 0.27 |
Inventory Turnover | 9.65 | 11.50 | 7.64 | 5.12 | 6.17 | 5.46 |
Quick Ratio | 1.33 | 1.35 | 0.97 | 4.50 | 2.99 | 3.80 |
Current Ratio | 1.53 | 1.50 | 1.07 | 4.76 | 3.23 | 3.97 |
Return on Equity (ROE) | -15.33% | -12.85% | -5.46% | 9.56% | -31.12% | -47.05% |
Return on Assets (ROA) | 1.54% | 3.15% | 0.13% | 0.55% | -11.45% | -12.88% |
Return on Invested Capital (ROIC) | 3.67% | 6.85% | 0.38% | 3.34% | -91.80% | -152.50% |
Return on Capital Employed (ROCE) | 3.10% | 6.20% | 0.20% | 0.90% | -21.90% | -20.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -6.28% | -15.27% | 109.05% | -1.77% | -3.36% | -3.86% |
FCF Yield | 0.06% | 6.98% | -4.42% | -9.99% | -4.99% | -2.90% |
Buyback Yield / Dilution | 0.75% | -0.63% | -3.27% | -0.58% | -3.28% | -6.83% |
Total Shareholder Return | 0.75% | -0.63% | -3.27% | -0.58% | -3.28% | -6.83% |